Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019123 · ClinicalTrials.gov registry record · Phase 2
Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
NCT00019123: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00019123 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019123, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Thalidomide may kill cancer cells by stopping the growth of new blood vessels to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients with HIV-associated Kaposi's sarcoma.
Interventions
- DRUG thalidomide
Trial Details
| Field | Value |
|---|---|
| Start Date | 1996-04 |
| Est. Completion | 2004-04 |
| Phase | Phase 2 |
What the finished NCT00019123 record still lists
NCT00019123 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which thalidomide is the first listed.
NCT00019123 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019123 about?
NCT00019123 is a clinical study titled "Thalidomide in Treating Patients With HIV-Associated Kaposi's Sarcoma". RATIONALE: Thalidomide may kill cancer cells by stopping the growth of new blood vessels to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients with HIV-associated Kaposi's sarcoma.
What is the current status of trial NCT00019123?
This trial is currently completed. It is a Phase 2 study. The study started on 1996-04. Estimated completion is 2004-04.
What interventions are being tested in trial NCT00019123?
The interventions under investigation include: thalidomide (DRUG).
Who is sponsoring clinical trial NCT00019123?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia